User:Templier~enwiki/sandbox

Templier~enwiki/sandbox
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	oral, inhalation
ATC code	R05CB15 (WHO) ;
Pharmacokinetic data
Protein binding	65%
Metabolism	hepatic
Elimination half-life	1-3 hours
Identifiers
	IUPAC name 2-[(2-oxothiolan-3-yl)carbamoylmethylsulfanyl]acetic acid;
CAS Number	84611-23-4;
PubChem CID	65632;
ChemSpider	59073 ;
UNII	76J0853EKA;
KEGG	D07383 ;
Chemical and physical data
Formula	C8H11NO4S2
Molar mass	249.309 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1SCCC1NC(=O)CSCC(=O)O;
	InChI InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12) ; Key:QGFORSXNKQLDNO-UHFFFAOYSA-N ;
	(verify)

This is the user sandbox of Templier~enwiki. A user sandbox is a subpage of the user's user page. It serves as a testing spot and page development space for the user and is not an encyclopedia article. Create or edit your own sandbox here.

Other sandboxes: Main sandbox | Template sandbox

Finished writing a draft article? Are you ready to request review of it by an experienced editor for possible inclusion in Wikipedia? Submit your draft for review!

Erdosteine is a mucolytic. Specifically it is a thiol derivative developed for the treatment of chronic obstructive bronchitis, including acute infective exacerbation of chronic bronchitis. Erdosteine contains two blocked sulfhydryl groups which are released following first-pass metabolism. The three active metabolites exhibit mucolytic and free radical scavenging activity. Erdosteine modulates mucus production and viscosity and increases mucociliary transport, thereby improving expectoration. It also exhibits inhibitory activity against the effects of free radicals produced by cigarette smoke.

Clinical studies in patients with chronic obstructive lung disease have demonstrated the efficacy and tolerability of erdosteine.^{[citation needed]} Erdosteine 300 mg twice daily reduced cough (both frequency and severity) and sputum viscosity more quickly and more effectively than placebo and reduced the adhesivity of sputum more effectively than bromhexine 30 mg twice daily.

Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier and more pronounced amelioration of clinical symptoms compared with placebo.

The LD50 ranges between 3,500-5,000 mg/kg.

Adverse effects

Adverse effects most commonly associated with Erdosteine are headache, epigastralia, nausea, and diarrhea.^[1]^[2]

Category:Antitussives Category:Carboxylic acids Category:Thioethers Category:Thiolactones Category:Amides

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

^ Marchioni CF, Polu JM, Taytard A et al. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int J Clin Pharmacol Ther 1995;33:612-618.
^ Mohanty KC, et al. Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment. J Clin Res 2001;4:35-39

[1] Marchioni CF, Polu JM, Taytard A et al. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int J Clin Pharmacol Ther 1995;33:612-618.

[2] Mohanty KC, et al. Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment. J Clin Res 2001;4:35-39

[1]

[2]